Page 64 - HIVMED_v21_i1.indb

Page 38 of 39 Guideline

18. Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral 44. Li JZ, Segal FP, Bosch RJ, et al. ART reduces T cell activation and immune
treatment regimens in Botswana. N Engl J Med. 2019;381(9):827–840. https:// exhaustion markers in HIV controllers. Clin Infect Dis. 2019;70:1636–1642.
doi.org/10.1056/NEJMoa1905230 45. Amanyire G, Semitala FC, Namusobya J, et al. Effects of a multicomponent
19. Raesima MM, Ogbuabo CM, Thomas V, et al. Dolutegravir use at conception – intervention to streamline initiation of antiretroviral therapy in Africa: A
Additional surveillance data from Botswana. N Engl J Med. 2019;381(9): stepped-wedge cluster-randomised trial. Lancet HIV. 2016;3(11):e539–e548.
885–887. https://doi.org/10.1056/NEJMc1908155
46. Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. The effect of same-day observed
20. Hill A, Waters L, Pozniak A. Are new antiretroviral treatments increasing the risks initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a
of clinical obesity? J Virus Erad. 2019;5(1):41–43. US public health setting. J Acquir Immune Defic Syndr. 2017;74(1):44–51.
21. Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different https://doi.org/10.1097/QAI.0000000000001134
prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803–815. https:// 47. Rosen S, Maskew M, Fox MP, et al. Initiating antiretroviral therapy for HIV at a
doi.org/10.1056/NEJMoa1902824 patient’s first clinic visit: The RapIT randomized controlled trial. PLoS Med.
22. Encore Study Group, Carey D, Puls R, et al. Efficacy and safety of efavirenz 400 2016;13(5):e1002015.
mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, 48. Uthman OA, Okwundu C, Gbenga K, et al. Optimal timing of antiretroviral
placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015; therapy initiation for HIV-infected adults with newly diagnosed pulmonary
15(7):793–802. tuberculosis: A systematic review and meta-analysis. Ann Intern Med.
23. Variava E, Sigauke FR, Norman J, et al. Brief report: Late Efavirenz-induced 2015;163(1):32–39.
ataxia and encephalopathy: A case series. J Acquir Immune Defic Syndr. 49. Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in
2017;75(5): 577–579. https://doi.org/10.1097/QAI.0000000000001451 human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin
24. Sinxadi PZ, Leger PD, McIlleron HM, et al. Pharmacogenetics of plasma efavirenz Infect Dis. 2011;52(11):1374–1383. https://doi.org/10.1093/cid/cir230
exposure in HIV-infected adults and children in South Africa. Br J Clin Pharmacol.
2015;80(1):146–156. https://doi.org/10.1111/bcp.12590 50. Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after
diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487–2498.
25. Sonderup MW, Maughan D, Gogela N, et al. Identification of a novel and severe
pattern of Efavirenz drug-induced liver injury in South Africa. AIDS. 51. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces
2016;30(9):1483–1485. https://doi.org/10.1097/QAD.0000000000001084 AIDS progression/death in individuals with acute opportunistic infections: A
multicenter randomized strategy trial. PLoS One. 2009;4(5):e5575. https://doi.
26. Jover F, Cuadrado JM, Roig P, Rodriguez M, Andreu L, Merino J. Efavirenz- org/10.1371/journal.pone.0005575
associated gynecomastia: Report of five cases and review of the literature.
Breast J. 2004;10(3):244–246. 52. Tucker JD, Bien CH, Easterbrook PJ, et al. Optimal strategies for monitoring
response to antiretroviral therapy in HIV-infected adults, adolescents, children
27. Sikora MJ, Rae JM, Johnson MD, Desta Z. Efavirenz directly modulates the and pregnant women: A systematic review. AIDS. 2014;28 Suppl 2:S151–S160.
oestrogen receptor and induces breast cancer cell growth. HIV Med.
2010;11(9):603–607. https://doi.org/10.1111/j.1468-1293.2010.00831.x 53. Hermans LE, Moorhouse M, Carmona S, et al. Effect of HIV-1 low-level viraemia
during antiretroviral therapy on treatment outcomes in WHO-guided South
28. Njuguna C, Swart A, Blockman M, et al. Cases of antiretroviral-associated African treatment programmes: A multicentre cohort study. Lancet Infect Dis.
gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker 2018;18(2):188–197. https://doi.org/10.1016/S1473-3099(17)30681-3
Hotline in South Africa. AIDS Res Ther. 2016;13:40.
29. Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine 54. Laprise C, De Pokomandy A, Baril JG, Dufresne S, Trottier H. Virologic failure
following persistent low-level viremia in a cohort of HIV-positive patients:
in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS. Results from 12 years of observation. Clin Infect Dis. 2013;57(10):1489–1496.
2013;27(6):939–950. https://doi.org/10.1093/cid/cit529
30. Behrens G, Rijnders B, Nelson M, et al. Rilpivirine versus efavirenz with 55. Chimukangara B, Lessells RJ, Rhee SY, et al. Trends in pretreatment HIV-1 drug
emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected resistance in antiretroviral therapy-naive Adults in South Africa, 2000–2016: A
patients with HIV-1 RNA </=100,000 copies/mL: Week 96 pooled ECHO/THRIVE pooled sequence analysis. EClinicalMedicine. 2019;9:26–34.
subanalysis. AIDS Patient Care STDS. 2014;28(4):168–175. https://doi.org/
10.1089/apc.2013.0310 56. Smith CJ, Sabin CA, Lampe FC, et al. The potential for CD4 cell increases in HIV-
positive individuals who control viraemia with highly active antiretroviral
31. Cohen C, Nieto-Cisneros L, Zala C, et al. Comparison of atazanavir with lopinavir/ therapy. AIDS. 2003;17(7):963–969. https://doi.org/10.1097/00002030-2003
ritonavir in patients with prior protease inhibitor failure: A randomized 05020-00004
multinational trial. Curr Med Res Opin. 2005;21(10):1683–1692. https://doi.
+
org/10.1185/030079905X65439 57. Loutfy MR, Genebat M, Moore D, et al. A CD4 cell count <200 cells per cubic
millimeter at 2 years after initiation of combination antiretroviral therapy is
32. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. associated with increased mortality in HIV-infected individuals with viral
lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week suppression. J Acquir Immune Defic Syndr. 2010;55(4):451–459.
analysis. AIDS. 2009;23(13):1679–1688.
58. Tuboi SH, Pacheco AG, Harrison LH, et al. Mortality associated with discordant
33. Venter WDF, Moorhouse M, Sokhela S, et al. Low-dose ritonavir-boosted responses to antiretroviral therapy in resource-constrained settings. J Acquir
darunavir once daily versus ritonavir-boosted lopinavir for participants with less Immune Defic Syndr. 2010;53(1):70–77. https://doi.org/10.1097/QAI.0b013
than 50 HIV RNA copies per mL (WRHI 052): A randomised, open-label, phase 3, e3181c22d19
non-inferiority trial. Lancet HIV. 2019;6(7):e428–e437. https://doi.org/10.1016/
S2352-3018(19)30081-5 59. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive
T-cell count and mortality among HIV-1-infected individuals with virological
34. Molina JM, Gallien S, Chaix ML, et al. Low-dose ritonavir-boosted darunavir in failure to all three antiretroviral-drug classes. Lancet. 2004;364(9428):51–62.
virologically suppressed HIV-1-infected adults: An open-label trial (ANRS 165 60. Paton NI, Kityo C, Hoppe A, et al. Assessment of second-line antiretroviral
Darulight). J Antimicrob Chemother. 2018;73(8):2129–2136. https://doi. regimens for HIV therapy in Africa. N Engl J Med. 2014;371(3):234–247.
org/10.1093/jac/dky181
61. La Rosa AM, Harrison LJ, Taiwo B, et al. Raltegravir in second-line antiretroviral
35. Insight Start Study Group, Lundgren JD, Babiker AG, et al. Initiation of therapy in resource-limited settings (SELECT): A randomised, phase 3, non-
antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. inferiority study. Lancet HIV. 2016;3(6):e247–e258. https://doi.org/10.1016/
2015;373(9):795–807. S2352-3018(16)30011-X
36. Temprano Anrs Study Group, Danel C, Moh R, et al. A trial of early antiretrovirals 62. Cohen K, Stewart A, Kengne AP, et al. A clinical prediction rule for protease
and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–822. inhibitor resistance in patients failing second-line antiretroviral therapy. J Acquir
37. Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention Immune Defic Syndr. 2019;80(3):325–329.
of HIV-1 transmission. N Engl J Med. 2016;375(9):830–839. https://doi. 63. Rhee SY, Grant PM, Tzou PL, et al. A systematic review of the genetic mechanisms
org/10.1056/NEJMoa1600693 of dolutegravir resistance. J Antimicrob Chemother. 2019;74(11):3135–3149.
38. Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk https://doi.org/10.1093/jac/dkz256
of HIV transmission in serodifferent couples when the HIV-positive partner is 64. Gupta RK, Gregson J, Parkin N, et al. HIV-1 drug resistance before initiation or
using suppressive antiretroviral therapy. JAMA. 2016;316(2):171–181. re-initiation of first-line antiretroviral therapy in low-income and middle-income
39. Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through countries: A systematic review and meta-regression analysis. Lancet Infect Dis.
2018;18(3):346–355.
condomless sex in serodifferent gay couples with the HIV-positive partner taking
suppressive antiretroviral therapy (PARTNER): Final results of a multicentre, 65. Lamorde M, Wang X, Neary M, et al. Pharmacokinetics, pharmacodynamics, and
prospective, observational study. Lancet. 2019;393(10189):2428–2438. pharmacogenetics of Efavirenz 400 mg once daily during pregnancy and post-
partum. Clin Infect Dis. 2018;67(5):785–790. https://doi.org/10.1093/cid/ciy161
40. Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV
transmission in serodiscordant male couples: An international, prospective, 66. Kaboggoza JP, Wang X, Neary M, et al. A lower dose of Efavirenz can be
observational, cohort study. Lancet HIV. 2018;5(8):e438–e447. https://doi. coadministered with Rifampicin and Isoniazid in tuberculosis patients. Open
org/10.1016/S2352-3018(18)30132-2 Forum Infect Dis. 2019;6(2):ofz035. https://doi.org/10.1093/ofid/ofz035
41. O’Brien M, Markowitz M. Should we treat acute HIV infection? Curr HIV/AIDS 67. Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus
Rep. 2012;9(2):101–110. https://doi.org/10.1007/s11904-012-0113-0 dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in
antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): Week
42. Krishnan S, Wilson EM, Sheikh V, et al. Evidence for innate immune system 48 results from two multicentre, double-blind, randomised, non-inferiority,
activation in HIV type 1-infected elite controllers. J Infect Dis. 2014;209(6): phase 3 trials. Lancet. 2019;393(10167):143–155.
931–939. 68. Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of
43. Crowell TA, Gebo KA, Blankson JN, et al. Hospitalization rates and reasons dolutegravir-rilpivirine for the maintenance of virological suppression in adults
among HIV elite controllers and persons with medically controlled HIV infection. with HIV-1: Phase 3, randomised, non-inferiority SWORD-1 and SWORD-2
J Infect Dis. 2015;211(11):1692–1702. https://doi.org/10.1093/infdis/jiu809 studies. Lancet. 2018;391(10123):839–849.
http://www.sajhivmed.org.za 56 Open Access